{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-26-000043","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.621825+00:00","generated_at":"2026-05-15T01:17:18.526808+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo","bullets":["Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.","FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.","U.S. FDA approved Foundayo (orforglipron) for obesity—first GLP-1 pill without food/water restrictions.","Acquired Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.","Pipeline progress: positive Phase 3 for Foundayo in T2D, Jaypirca combo in CLL, and retatrutide in T2D."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-26-000043","json":"https://secwatch.observer/filing/0000059478-26-000043.json","markdown":"https://secwatch.observer/filing/0000059478-26-000043.md","text":"https://secwatch.observer/filing/0000059478-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/lly-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:17:18.526808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0020f2abd9eb9dc86d5f0fad1a4d64ca38835419","claim":"ELI LILLY & Co reported FY 2026 results: revenue 82.0 billion to 85.0 billion, EPS 35.50 to 37.00. Guidance raised.","evidence_excerpt":"Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2026"},{"label":"Revenue","value":"82.0 billion to 85.0 billion"},{"label":"EPS","value":"35.50 to 37.00"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}]},{"claim_id":"f1508fcbb9e0fe43c2b66e19d456c99c15363b06","claim":"ELI LILLY & Co reported Q1 2026 results: revenue 19,799, net income 7,396, EPS 8.26.","evidence_excerpt":"Revenue $ 19,799 $ 12,729 56% Net income – Reported 7,396 2,759 168% Earnings per share – Reported 8.26 3.06 170%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2026"},{"label":"Revenue","value":"19,799"},{"label":"Net income","value":"7,396"},{"label":"EPS","value":"8.26"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}